Quick Answer
Allogene Therapeutics, Inc. reported Diluted EPS of $0.87 per share (loss) for fiscal year 2025.
Allogene Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.87 | +34.1% |
| 2024 | -$1.32 | +36.8% |
| 2023 | -$2.09 | +12.2% |
| 2022 | -$2.38 | -77.6% |
| 2021 | -$1.34 | +35.6% |
| 2020 | -$2.08 | -13.7% |
| 2019 | -$1.83 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | +40.6% | +17.4% |
| June 30, 2025 | -$0.23 | +34.3% | +17.9% |
| March 31, 2025 | -$0.28 | +26.3% | +12.5% |
| September 30, 2024 | -$0.32 | +13.5% | +8.6% |
| June 30, 2024 | -$0.35 | +35.2% | +7.9% |
| March 31, 2024 | -$0.38 | +44.9% | -2.7% |
| September 30, 2023 | -$0.37 | +36.2% | +31.5% |
| June 30, 2023 | -$0.54 | -3.8% | +21.7% |
- Allogene Therapeutics, Inc. showed an increase of +34.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Allogene Therapeutics, Inc.’s diluted eps has grown by 52.5% (from $1.83 per share (loss) to $0.87 per share (loss)).
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: